Microvascular Therapeutics

Transforming ultrasound from imaging to cure.

[Craig Everett @DrCraigEverett]

https://t.co/kGDL5dSqOr

[Biocom @Biocom]

Happy #NewMemberMonday!
💼 @Calibre1Search places top talent into iconic corporate giants and VC-backed companies
🏙️ @Fremont_CA delivers public service and safety for everyone who lives and works in Fremont
💡 @nanobbl pioneers ultrasound contrast agents and theranostics

[Craig Everett @DrCraigEverett]

Congratulations to Microvascular Therapeutic of Tucson, AZ, one of the 14 winners of the 2025 @Pepperdine @GraziadioSchool Most Fundable Companies Competition in Malibu, CA. Microvascular Therapeutics develops patented ultrasound microbubble and nanobubble platforms, targeting multi-billion-dollar cardiovascular, oncology, and neurology markets by transforming ultrasound from diagnostic imaging to cure. https://t.co/TUs5N0E4FA @nanobbl @TucsonStar @tucson_az @TucsonSmallBiz @azbiz

[Microvascular Therapeutics @nanobbl]

We received positive results from our phase II study of our drug candidate, CardiSon, a microbubble contrast agent for echocardiography. https://t.co/PgL31qecFs

[Microvascular Therapeutics @nanobbl]

Evan Unger, CEO and Founder of MVT, was honored to present MVT at the Biotech Showcase last week, thanks to NIH Seed. We are grateful to the
@nihseed for their ongoing support of MVT's technology and growth.

[Microvascular Therapeutics @nanobbl]

We are thrilled to have completed enrollment for our Phase II clinical study for our new contrast agent MVT-100 https://t.co/lH09SQC2JP

[Microvascular Therapeutics @nanobbl]

Dr. Evan Unger, CEO and Founder of Microvascular Therapeutics (MVT), has been awarded the 2024 Harry Fischer Award by Contrast Media Research (CMR) in recognition of his exceptional contributions to the field of contrast media research. https://t.co/cC91CHmcWg

[Microvascular Therapeutics @nanobbl]

Thank you to H7 Bio Capital for having us. Out of hundereds of applicants we were one of four selected to pitch at their accelerator event. It was a great opportunity to meet with investors and showcase our technology.